JP7005772B2 - 眼科疾患の処置 - Google Patents

眼科疾患の処置 Download PDF

Info

Publication number
JP7005772B2
JP7005772B2 JP2020536578A JP2020536578A JP7005772B2 JP 7005772 B2 JP7005772 B2 JP 7005772B2 JP 2020536578 A JP2020536578 A JP 2020536578A JP 2020536578 A JP2020536578 A JP 2020536578A JP 7005772 B2 JP7005772 B2 JP 7005772B2
Authority
JP
Japan
Prior art keywords
weeks
antibody
vegf
treatment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020536578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506947A (ja
Inventor
ウェイカート，ロバート・ジェームズ
オズボーン，アーロン
サーニ，ジャヤシュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2021506947A publication Critical patent/JP2021506947A/ja
Priority to JP2022000341A priority Critical patent/JP7273204B2/ja
Application granted granted Critical
Publication of JP7005772B2 publication Critical patent/JP7005772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020536578A 2018-02-06 2019-02-05 眼科疾患の処置 Active JP7005772B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000341A JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000341A Division JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置

Publications (2)

Publication Number Publication Date
JP2021506947A JP2021506947A (ja) 2021-02-22
JP7005772B2 true JP7005772B2 (ja) 2022-02-10

Family

ID=65352014

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2020536578A Active JP7005772B2 (ja) 2018-02-06 2019-02-05 眼科疾患の処置
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置
JP2023073187A Active JP7646727B2 (ja) 2018-02-06 2023-04-27 眼科疾患の処置
JP2025034493A Pending JP2025084977A (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034492A Pending JP2025084976A (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022000341A Active JP7273204B2 (ja) 2018-02-06 2022-01-05 眼科疾患の処置
JP2023073187A Active JP7646727B2 (ja) 2018-02-06 2023-04-27 眼科疾患の処置
JP2025034493A Pending JP2025084977A (ja) 2018-02-06 2025-03-05 眼科疾患の処置
JP2025034492A Pending JP2025084976A (ja) 2018-02-06 2025-03-05 眼科疾患の処置

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (2) KR20240093772A (enExample)
CN (4) CN119733046A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TW202535932A (enExample)
WO (1) WO2019154776A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
IL276158B2 (en) 2018-01-26 2024-07-01 Univ California Methods and preparations for the treatment of angiogenic disorders using anti-VEGF factors
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
CN119303075A (zh) * 2019-08-06 2025-01-14 豪夫迈·罗氏有限公司 眼科疾病的个性化治疗
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
CN116323663A (zh) * 2020-09-04 2023-06-23 豪夫迈·罗氏有限公司 与vegf-a和ang2结合的抗体及其使用方法
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
EP4313148A4 (en) * 2021-03-30 2025-02-19 Abpro Corporation METHODS FOR TREATING CHOROIDAL NEOVASCULARIZATION WITH MULTI-SPECIFIC ANTI-ANG2 X VEGF ANTIBODIES
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
EP4392038A4 (en) * 2021-08-23 2025-06-11 Avirmax Biopharma Inc. COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527064A (ja) 2012-07-13 2015-09-17 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
JP2016528166A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR100870353B1 (ko) 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
DE69830901T2 (de) 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011090762A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Heterodimer binding proteins and uses thereof
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
SG10202111177VA (en) * 2011-01-13 2021-11-29 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2859667C (en) 2011-12-20 2022-05-24 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
RS59263B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
CA3098856C (en) * 2012-08-21 2023-10-17 Opko Pharmaceuticals, Llc Ophthalmic liposome formulations for treating posterior segment disease
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3230316B1 (en) * 2014-12-11 2022-01-05 Bayer HealthCare LLC Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
EP3454903A4 (en) 2016-05-13 2020-08-19 Askgene Pharma, Inc. NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF
AU2017286676B2 (en) * 2016-06-17 2024-07-25 F. Hoffmann La-Roche Ag Purification of multispecific antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015527064A (ja) 2012-07-13 2015-09-17 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
JP2016528166A (ja) 2013-04-29 2016-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chakravarthy U. et al.， The novel bispecific monoclonal anti-VEGF/anti-Ang2 antibody RG7716 shows promise in wet age-related macular degeneration patients with suboptimal response to prior anti-VEGF monotherapy， Investigative Ophthalmology & Visual Science, 2016 ARVO Annual Meeting Abstract[online](retrieved on 2021 Aug 2)，2016年09月，Vol.57, Issue 12，retrieved from the Internet<URL:https://iovs.arvojournals.org/article.aspx?articleid=2558448>
EMBO Mol Med.，2016年，8，p.1265-1288
Ophthalmology Retina，2017年，1(6)，p.474-485
Study NCT02484690, Clinicaltrials.gov[online](retrieved on 2020 Nov 30)，2018年02月02日，retrieved from the Internet<URL:https://clinicaltrials.gov/ct2/history/NCT02484690?V_15=View#StudyPageTop>
Study NCT02699450，Clinicaltrials.gov[online](retrieved on 2021 Aug 2)，2017年12月21日，retrieved from the Internet<URL:https://clin icaltrials.gov/ct2/history/NCT02699450?V_9=View#StudyPageTop>

Also Published As

Publication number Publication date
JP2022046738A (ja) 2022-03-23
CN119909169A (zh) 2025-05-02
KR20240093772A (ko) 2024-06-24
JP2025084977A (ja) 2025-06-03
JP7273204B2 (ja) 2023-05-12
TWI831764B (zh) 2024-02-11
TW202535932A (zh) 2025-09-16
IL276383A (en) 2020-09-30
CA3088355A1 (en) 2019-08-15
AU2025220842A1 (en) 2025-09-11
EP3749359A1 (en) 2020-12-16
KR20200119274A (ko) 2020-10-19
WO2019154776A1 (en) 2019-08-15
TWI885720B (zh) 2025-06-01
CN119770646A (zh) 2025-04-08
MX2020007527A (es) 2020-09-09
IL276383B1 (en) 2023-09-01
CN119733046A (zh) 2025-04-01
JP2025084976A (ja) 2025-06-03
AU2019219004B2 (en) 2025-06-05
AU2025220841A1 (en) 2025-09-11
IL276383B2 (en) 2024-01-01
TW202419464A (zh) 2024-05-16
CN111699004A (zh) 2020-09-22
JP7646727B2 (ja) 2025-03-17
JP2021506947A (ja) 2021-02-22
US20210139576A1 (en) 2021-05-13
TW202000700A (zh) 2020-01-01
SG11202006712XA (en) 2020-08-28
JP2023099094A (ja) 2023-07-11
AU2019219004A1 (en) 2020-07-16
US20230416353A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7005772B2 (ja) 眼科疾患の処置
TWI881273B (zh) 眼科疾病之個人化治療
KR20250166355A (ko) 안과 질환의 치료
WO2025219504A1 (en) Treatment of ophthalmologic diseases
HK40065038A (en) Personalized treatment of ophthalmologic diseases
HK40034720A (zh) 眼科疾病的治疗
HK40065038B (zh) 眼科疾病的个性化治疗

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200730

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220105

R150 Certificate of patent or registration of utility model

Ref document number: 7005772

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153